Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
Assess the safety and toleration of CP-464,005 and Inhaler following 1-year (52 week)
 administration to Type 1 and Type 2 diabetes patients (non-smokers)
Pfizer announced in October 2007 that it would stop marketing CP-464,005. At that time
 recruitment for study, A2171105 was placed on hold. Nektar, the company from which Pfizer
 licensed CP-464,005, announced on April 9, 2008 that it had stopped its search for a new
 marketing partner. As a result, study A2171105 was terminated on April 10, 2008. Neither
 safety nor efficacy reasons were the cause of the study termination.
Inclusion Criteria:

 -  Patients who have been diagnosed with Type 1 or Type 2 diabetes for at least 1 year,
 based on the diagnostic criteria for diabetes.

 Exclusion Criteria:

 -  Patients who have smoked during the 6 months prior to screening (smoking shall be
 prohibited during the term of this study, as well)

 -  Patients exhibiting pulmonary function test (spirometry) abnormalities (FVC or FEV1 <
 70% of predicted) ) at Week -4.